ClinicalTrials.gg
CompletedNCT04914273EXPLOREUpdated Oct 15, 2024

Use of Exhaled Particles to Assess Lung Pharmacokinetics

An interventional study of Inhalation Spray and Tablet in Healthy and Lung Pharmacokinetic, sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Fraunhofer-Institute of Toxicology and Experimental Medicine · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This research project in humans aims at increasing the general understanding of lung pharmakokinetic by sampling exhaled particles. The central hypothesis of this study is that pharmacokinetics of Salbutamol (model drug) can be monitored in exhaled particles.

Read the detailed description

The aim of the present study is to increase the general understanding of lung pharmakokinetic by systematically sampling exhaled particles at pre-specified quantities to reproduce and extent existing pilot data. For comparison, samples of blood plasma and nasal filter samples (nasosorption) will be collected for pharmakokinetic analyzes. Nasosorption will be performed to explore the possibility of detecting drug concentrations in nasal filter paper samples.

Salbutamol will be administered by inhalation and orally in a cross-over study design and both application routes shall be comparised regarding the detection of pharmakokinetic data. The aim of the study is not to generate safety or efficacy data of the selected licensed drugs. The choice of drugs is based on general considerations regarding therapy of airway diseases and the physical-chemical properties of the compounds. It is not driven by the compounds per se.

02

Conditions studied

  • Healthy
  • Lung Pharmacokinetic
03

In context

Lead sponsor

Fraunhofer-Institute of Toxicology and Experimental Medicine is the lead sponsor of 38 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written .
  2. Healthy male and female subjects, aged 18-65 years. Women will be considered for inclusion if they are:

    Not pregnant, as confirmed by pregnancy test (see flow chart), and not nursing. Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or , with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit).

    Of and using a highly effective method of during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the first dose of study medication until at least 72 hours after treatment -, implants, injectables, combined oral contraceptives, hormonal IUDs or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap).

  3. between 18 and 32 kg/m2
  4. Normal lung function with predicted ≥ 80% and FEV1/FVC ≥ 70% at screening V1 ( or performed within 12 months prior to the screening visit at Fraunhofer ITEM and no evidence of clinical relevant abnormal findings in the lung function in the previous year before screening in the anamnesis).
  5. Nonsmokers with a history of less than 1 pack year having been nonsmokers for at least the last 12 months
  6. Emission of acceptable quantities of exhaled particles at screening (>200ng particle mass within 15 min)

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal findings, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study
  2. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, , hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to asthma, chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
  3. Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for pain relief, oral medication, hormonal replacement therapy, dietary and vitamin supplements
  4. Clinically relevant history of allergy as judged by the investigator
  5. Intolerance or to salbutamol
  6. Infections of the lower respiratory tract within 4 weeks before visit 1, visit 2 or visit 3. These patients can be rescreened starting from visit 1.
  7. Participation in another clinical trial with an IMP 30 days or five half-lives, whichever is longer, prior to enrollment
  8. History of drug or alcohol abuse
  9. Risk of non-compliance with study procedures
  10. Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
  11. Significant nasal deformity, recent nasal surgery or obstructing nasal polyps
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Sequence A: 1. Ingestion 2. Inhalation

    Group A is treated in the following sequence: 1. oral drug 2. inhalative drug

    Drug: Inhalation Spray · Drug: Tablet

  • Experimental
    Sequence B: 1. Inhalation 2. Ingestion

    Group B is treated in the following sequence: 1. inhalative drug 2. oral drug

    Drug: Inhalation Spray · Drug: Tablet

Interventions

  • DrugInhalation Spray

    400 mcg salbutamol administered per metered dose inhaler

  • DrugTablet

    8 mg salbutamol administered per tablet for ingestion

06

What researchers measure

Primary outcomes

  1. Salbutamol concentration assessed in exhaled particles over 5 hours after inhaled versus oral administration

    Time frame: Before, 0 min, 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 270 min, 300 min after drug administration

Secondary outcomes

  1. Salbutamol concentration assessed in blood plasma over 5 hours after inhaled versus oral administration

    Time frame: Before, 0 min, 15 min, 35 min, 55 min, 75 min, 135 min, 195 min, 255 min, 285 min, 315 min after drug administration

  2. Salbutamol concentration assessed in nasal filter samples (nasosorption) over 5 hours after inhaled versus oral administration

    Time frame: Before, 0 min, 15 min, 35 min, 55 min, 75 min, 135 min, 195 min, 255 min, 285 min, 315 min after drug administration

  3. Safety and tolerability of the sampling method by assessing adverse events

    Time frame: Day 1 to Day 18

07

Study locations

1 site
  • Fraunhofer Institute for Toxicology and Experimental Medicine
    Hannover, Lower Saxony 30625, Germany
08

References and documents

Publications

  • Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the healthy human lung--a systematic analysis in relation to pulmonary function variables. J Aerosol Med Pulm Drug Deliv. 2010 Dec;23(6):371-9. doi: 10.1089/jamp.2009.0809. Epub 2010 May 25. PubMed 20500095 ↗
  • Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the human lungs in airway obstruction. J Aerosol Med Pulm Drug Deliv. 2015 Feb;28(1):52-8. doi: 10.1089/jamp.2013.1104. Epub 2014 Jun 10. PubMed 24914577 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Aug 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2021
First posted
Jun 4, 2021
StartActual
Jun 14, 2021
Primary completionActual
Aug 3, 2021
CompletionActual
Aug 3, 2021
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04914273
Lead sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
Collaborators
AstraZeneca
Responsible party
Prof. Dr. Jens Hohlfeld, MD (Prof. Dr. Jens M Hohlfeld, Fraunhofer-Institute of Toxicology and Experimental Medicine) — Principal investigator
First posted
Jun 4, 2021
Start date
Jun 14, 2021
Primary completion
Aug 3, 2021
Completion
Aug 3, 2021
Last update
Oct 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion